Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Closing in on cancer | Merus
Genmab Acquires Merus for $8B, Boosts Cancer Care | Faisal Zubair ...
Merus grabs first-in-class US approval for NRG1 cancer drug | pharmaphorum
Genmab Agrees to Buy Cancer Drugmaker Merus for $8 Billion
Merus makes push into colorectal cancer with early positive data
Merus Shares Surge with Impressive Interim Cancer Trial Data
Merus Will Have a Best-in-Class Treatment for Head and Neck Cancer ...
Merus Cancer Drug Shows 63% Response Rate in Trial, Reports Q2 Earnings ...
Denmark's Genmab buys Dutch cancer drugmaker Merus for $8 bn ...
Genmab to Acquire Merus for $8B, Expanding Bispecific Antibody Cancer ...
Merus Shares Surge Amid Promising Cancer Trial Updates
Merus stock gains on cancer drug data (MRUS:NASDAQ) | Seeking Alpha
Genmab to Acquire Merus for $8 Billion, Expanding Cancer Drug Pipeline ...
Genmab Acquires Dutch Cancer Drugmaker Merus for $8 Billion
Merus cancer bispecific lives up to investors' expectations
Genmab Shells Out $8 Billion for Merus | Cancer Discovery News ...
Genmab agrees $8bn takeover of cancer biotech Merus | pharmaphorum
Genmab: $8 Billion Deal to Acquire Merus Expands Cancer Pipeline ...
Merus wins in head-to-head with Bicara for head and neck cancer
Danish Genmab Acquires Dutch Cancer Treatment Firm Merus for $8 Billion ...
Genmab Acquires Merus for $8 Billion to Advance Cancer Therapies
Genmab Makes $8 Billion Bet On Merus With Potential Cancer Breakthrough
Genmab Buys Rising Cancer Star Merus for $8B - BioSpace
Genmab Strikes $8 Billion Deal for Cancer Treatment Maker Merus
Merus touts cancer drug's strong profile with new data drop
Merus shares dip as lung cancer data reveal 3 patient deaths
Merus partners with oncology institute on cancer treatments - Clinical ...
Merus Stock Surges Over 35% On Strong Phase 2 Cancer Trial Results ...
Oppenheimer positive on CytomX after Merus colon cancer data - TipRanks.com
Genmab to buy Dutch cancer drugmaker Merus for $8 billion | Reuters
ASCO 2024: Merus touts positive Phase II data for head and neck cancer ...
Genmab to buy cancer biotech Merus for $8B
Genmab to acquire closely watched cancer drug in $8B Merus buyout ...
Effective Cancer Therapy Presentation Design by Merus | SlideGenius
ASCO25: Merus bispecific appears to boost survival in head and neck cancer
Merus drug and Keytruda shrank tumors in patients with head and neck cancer
Merus Shares Soar 3.24% On Positive Cancer Study Update
Early Merus drug data show survival boost in head and neck cancer | STAT
#closeinoncancer | Merus N.V.
04 December 2024: Merus gains accelerated approval for first-in-class ...
Merus Presents First in Human Data on MCLA-129 at the 34th EORTC/NCI ...
Merus N.V. on LinkedIn: Merus
IRB Barcelona and Merus form a research collaboration to develop ...
Rays of Resilience: Navigating Hope Amidst Meru’s Cancer Puzzle - Radio ...
Merus Collaborates with Partner Therapeutics to Commercialize ...
Funding the Next Generation of Cancer Therapies
Merus Announces Publication of an Abstract on Petosemtamab in ...
It’s #WorldCancerDay and our focus is on patients living with cancer ...
Merus advances the world's first LGR5-targeted bispecific antibody into ...
Merus's Preclinical Bispecific Zeno Demonstrates Efficacy in Cancer Models
Homepage - Merus Gastroenterology & Gut Health | John's Creek, GA
Merus, Caris Life Sciences Collaborate to Detect NRG1 Fusions in Cancer ...
Merus N.V.: Making Progress (NASDAQ:MRUS) | Seeking Alpha
About Us | Merus
#nejm #closeinoncancer | Merus N.V.
Merus N.V. - 2025 ASCO® Annual Meeting
#closeinoncancer #hnscc #gastrointestinalcancer | Merus N.V.
Genmab's $8B Acquisition of Merus: A New Era in Head & Neck Cancer ...
US FDA extends review of Merus' gene-targeting cancer therapy | Reuters
Pipeline | Merus N.V.
Merus's next shot is colorectal cancer | ApexOnco - Clinical Trials ...
Merus N.V. on LinkedIn: #closeinoncancer #cancerresearchsaveslives
The Importance of Colonoscopy Screening: Detecting Colon Cancer Early ...
Merus Stock Catapults To Record High After Beating Expectations In ...
Merus CEO: We’re really optimistic about the potential for our drug in ...
Merus' NRG1+ drug responses edge up in tough pancreatic cancer
Genmab adquirirá Merus en un acuerdo de 8 millones de dólares centrado ...
US drug body approves Merus' therapy for lung, pancreatic cancer ...
Gilead, Merus Strike Deal to Develop Novel Trispecific T-Cell ...
Clinical Trials | Merus
Genmab Will Buy Cancer-Focused Merus For $8 Billion | Investor's ...
Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1 ...
Merus N.V. | LinkedIn
Merus and Partner Therapeutics Announce License Agreement
Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer ...
Foundation Medicine and Merus Partner to Develop Companion Diagnostic ...
SURVIVORSHIP SYMPOSIUM | Head & Neck Cancer Alliance
Merus Buyout Rumor Gets Retail Traders Buzzing — Genmab Said To Be ...
Dutch oncology company Merus to be acquired for €6.8B
Exciting development for head and neck cancer patients and a proud ...
Slide 20
Merus’ Petosemtamab Interim Data Demonstrates Clinically Meaningful ...
Merus’ Zeno Interim Data Continues to Demonstrate Robust and Durable ...
Merus’ Bispecific Shows ‘Best in Disease’ Profile in Head-and-Neck ...
Merus: Riding The Bispecific Wave In Oncology (NASDAQ:MRUS) | Seeking Alpha
Merus’ Zenocutuzumab, a HER2-HER3 Bispecific Antibody, Successfully ...
Preventing Colorectal Cancer: The Vital Role of Colonoscopy Screening ...
MRUS Stock Forecast, Price & News (Merus) - MarketBeat
#ASCO24: Merus, touting more Phase 2 data, plots pivotal head and neck ...
AACR Annual Meeting Coverage | AACR Conference Coverage | AACR 2025
/author-service-images-prod-us-east-1.publishing.aws.arc.pub/morningstar/ca9ef979-0207-4e37-b392-91618ebc1841.jpg)
)
